<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781933</url>
  </required_header>
  <id_info>
    <org_study_id>ICAN</org_study_id>
    <nct_id>NCT04781933</nct_id>
  </id_info>
  <brief_title>Interest in &quot;Combo&quot; (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement</brief_title>
  <acronym>ICAN</acronym>
  <official_title>Interest in &quot;Combo&quot; (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mativa-Tech SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mativa-Tech SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this bicentre, prospective, placebo-controlled, double-blind, randomized,&#xD;
      interventional study is to assess for the first time the effects of a Combo with probiotics&#xD;
      and dietary supplements compared to placebo for non-alcoholic steatohepatitis (NASH) patients&#xD;
      with mild or severe fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver-related mortality is increased 10-fold in NASH patients compared with the general&#xD;
      population. Currently, there are no established pharmacotherapies for NASH patients. The gut&#xD;
      microbiota has a major contributing role in the development of NASH with leaky gut,&#xD;
      inflammation, oxidative stress and impaired microbiota. Restoring the microbiota symbiosys&#xD;
      could be a new way of resolution of NASH.&#xD;
&#xD;
      The aim of this trial is to evaluate the efficacy of the Combo, association of probiotics&#xD;
      (Lactobacillus rhamnosus GG, Bifidobacterium breve BR03, Lactobacillus plantarum) and&#xD;
      Glutamine, Quercetin, Vitamin E, Curcumin, Silybin, Pectin by means of histological&#xD;
      resolution of NASH without progression of fibrosis, after 52 weeks, in 60 NASH patients with&#xD;
      mild to severe fibrosis.&#xD;
&#xD;
      To confirm a histological diagnosis of NASH and proof efficacy of the Combo, a liver biopsy&#xD;
      will be performed prior to screening as well as at the end of supplemental phase&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NASH reduction: the main expected benefit is resolution of NASH, and no worsening of fibrosis</measure>
    <time_frame>At one year</time_frame>
    <description>Evolution of the SAF score, a composite histological score taking into account the improvement of Steatosis, histological activity and liver fibrosis. (Expected decrease in the median of 1.0; before treatment expected to 4.5 after expected treatment at 3.5), an improvement of 30%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial correlation of NASH parameters (SAF, FIB4, NAFLD and liver stiffness) and symbiosis parameters (stool analysis 16S, biological data specific to symbiosis).</measure>
    <time_frame>At the screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow up of liver stiffness throughout the study</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Follow up of Biological Scores (FIB4, NAFLD) throughout the study</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Follow up of symbiosis throughout the study, analysis of stool 16S of the microbiota and measurement of the biological parameters of the symbiosis; correlation with the evolution of NASH.</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Follow up of metabolic syndrome settings throughout the study : weight, waistline, blood pressure, Glycemia, Insulinemia, Gycated Hemoglonin level, Ferritinaemia, Triglyceridemia, HDL Cholesterol, LDL Cholesterol, Apolipoproteine A1, Homa score.</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Treatment with Combo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 dietary supplements will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 placebos will be given</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Treatment with Combo</intervention_name>
    <description>Treatment with Combo</description>
    <arm_group_label>Treatment with Combo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment with placebo</intervention_name>
    <description>Treatment with placebo</description>
    <arm_group_label>Treatment with Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of moderate to severe NASH :&#xD;
&#xD;
               -  chronic liver disease: biological abnormalities for more than 6 months&#xD;
                  characteristic ultrasound aspects&#xD;
&#xD;
               -  metabolic syndrome&#xD;
&#xD;
               -  liver stiffness assessed by FibroScan &gt; or at 8kPa. (10 measures validated with&#xD;
                  median IQR &lt; 30%)&#xD;
&#xD;
               -  histologic evidence of NASH with fibrosis stage (METAVIR score) F2 or F3&#xD;
&#xD;
          -  Adults&#xD;
&#xD;
          -  Affiliated to a social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Excessive alcohol consumption (&gt;100g/week)&#xD;
&#xD;
          -  Cirrhosis (F4)&#xD;
&#xD;
          -  hepato-cellular carcinoma&#xD;
&#xD;
          -  Hepatitis from Corticosteroids, Methotrexate, Amiodarone, Tamoxifen&#xD;
&#xD;
          -  Hepatitis from Amitriptyline, Imipramine, Clozapine, Diclofenac&#xD;
&#xD;
          -  Viral hepatitis&#xD;
&#xD;
          -  Auto immune hepatitis&#xD;
&#xD;
          -  anticoagulant therapy&#xD;
&#xD;
          -  antibiotics in the 2 months prior to inclusion&#xD;
&#xD;
          -  allergic to soya, aspirin, fish, E110 dye, Maltodextrin&#xD;
&#xD;
          -  poorly controlled diabetes (Glycated Hemoglobin &gt;8%)&#xD;
&#xD;
          -  inclusion in a drug interventional trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hervé HAGEGE, Ph D</last_name>
    <phone>01 57 02 27 30</phone>
    <email>herve.hagege@chicreteil.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luc LEITZ</last_name>
    <email>luc.heitz@mativa-tech.com</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Hervé Hagege</investigator_full_name>
    <investigator_title>Pr</investigator_title>
  </responsible_party>
  <keyword>Combo</keyword>
  <keyword>liver stiffness</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>dietary supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

